This retrospective cohort analysis quantifies survival and major morbidity in patients aged 50 to 69 years receiving bioprosthetic vs mechanical aortic valve replacement.
In a randomized clinical trial involving 241 patients undergoing transcatheter aortic valve replacement, Abdal-Wahab and co-authors found that use of balloon-expandable valves resulted in a greater rate of device success than use of self-expandable valves.
This randomized clinical trial compares the effects of use vs nonuse of a cerebral embolic protection device during transcatheter aortic valve implantation (TAVI) on MRI-detected brain lesions in patients with severe aortic stenosis undergoing TAVI.
In an analysis of data from 369 226 Medicare beneficiaries who underwent aortic valve replacement between 1999 and 2011, Barreto-Filho and coauthors examined trends in procedure rates, the association with coronary artery bypass graft surgery, and patient outcomes.
In this cohort study, there was no survival difference at 15 years among older patients who underwent mechanical prosthetic vs bioprosthetic mitral replacement.